German biotechnology company BioNTech SE and Chinese pharmaceutical company Shanghai Fosun Pharmaceutical (Fosun) will launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China, Reuters news agency reported on Wednesday.
In a statement, BioNTech and Fosun said that this vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Centre for Disease Control and Prevention to assess safety and immunogenicity, eyeing future approval in China.
In addition, BioNTech is working with US pharmaceutical company Pfizer Inc on the vaccine.
The companies had said last week they were hoping to win approval in the US and Europe this year, after trial results showed the compound had a 95% efficacy rate and caused no serious side effects.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients